Prognostic importance of myocardial injury in critically ill dogs with systemic inflammation

Langhorn, Rebecca; Oyama, M. A.; King, L. G.; Machen, M. C.; Trafny, D. J.; Thawley, V.; Willesen, Jakob; Tarnow, Inge; Kjelgaard-Hansen, Mads

Published in:
Journal of Veterinary Internal Medicine

DOI:
10.1111/jvim.12105

Publication date:
2013

Document Version
Early version, also known as pre-print

Citation for published version (APA):
Critical illness can be defined as important metabolic derangements that require intensive care to sustain life or enhance metabolic stability. Critically ill patients have a high risk of death, and the ability to measure markers of deterioration is crucial as it could allow the possibility to intervene with additional or alternate treatment. Prognostic composite scores are continuously being examined and developed in human and veterinary medicine, with main components being markers of organ dysfunction. Two diagnosis-independent severity scores have been validated for use in dogs, the acute patient physiologic and laboratory evaluation (APPLE) and the survival prediction index (SPI2). These scores, however, do not contain any markers of myocardial injury, and contribution of such injury to the prognostic capacity of severity scores in dogs is unexplored.

In humans, cardiac troponins I and T (cTnI and cTnT) have long been recognized as sensitive and specific markers of myocardial injury which are most commonly used in the diagnosis of acute myocardial infarction (AMI). However, there is an increasing awareness that myocardial injury occurs much more frequently than previously suspected in critically ill human patients with primary disease of noncardiac origin. In the noncardiologic human ICU, sepsis is the most common cause of death. Myocardial injury in patients with sepsis or other causes of systemic inflammation is presumably caused by hemodynamic changes, toxic effects of cytokines, microthrombosis, and ischemia-reperfusion injury. This myocardial injury, though often clinically unrecognized, has been
associated with increased morbidity and death, and detecting and treating it might be all the more important as it might be caused by cardiomyocyte leakage of the cytosolic pool of troponins rather than cell necrosis, thereby being potentially reversible. Interestingly, no established correlation between cardiac troponin concentrations and prognostic composite scores in humans, such as the acute physiology and chronic health evaluation (APACHE) II or III or the simplified acute physiology score (SAPS) II, has been found. As the significance of myocardial injury or dysfunction was not included when these models were developed, this had led to speculation that cardiac troponins can provide additional prognostic information, and several human studies have concluded that cardiac troponin remains an independent prognosticator even after stratifying for degree of illness severity. In dogs, the established prognostic composite scores, APPLE and SPI2, also lack markers of myocardial injury.

The objective of this study was to investigate the presence and prognostic relevance of myocardial injury in critically ill dogs with systemic inflammation. It was hypothesized that the presence of myocardial injury would be predictive of short-term mortality in dogs admitted to the ICU with systemic inflammation, and that it would provide additional prognostic information when added to established prognostic composite scores in dogs. As the myocardial injury is thought to be mediated by inflammatory cytokines, a 2nd objective of the study was to investigate the possible contribution of cytokines to prognostic composite models with an included marker of myocardial injury.

Materials and Methods

Study Population

Over a 3-month period from May to July 2011, critically ill client-owned dogs were included at the time of admission to the ICU at the Veterinary Hospital of the University of Pennsylvania (VHUP). The study protocol was approved by the VHUP Privately Owned Animal Protocol Committee and the University of Pennsylvania Institutional Animal Care and Use Committee, and informed consent was obtained from all owners. The study was performed as a prospective cohort study with 28 days of follow-up. Dogs that had been diagnosed with cardiac disease before admission were excluded. An echocardiographic examination was performed by a board-certified cardiologist or cardiology resident and a 5-min EKG recorded. Dogs in which evidence of structural primary heart disease (symptomatic or asymptomatic) was identified were further excluded. Likewise, dogs recently treated with a known cardiotoxic drug (eg, doxorubicin) were excluded. Finally, dogs were excluded if data collection posed a risk to the dog (ie, if the dog was too small for collection of the required blood volume, had severe respiratory distress, or severe anemia), if study participation was declined by the owner or attending clinician, or if they were euthanized for reasons other than a grave prognosis for survival (eg, financial reasons).

Systemic inflammation at ICU admission was defined as a serum concentration of C-reactive protein (CRP) >35 mg/L within the first 24 hours of admission. Dogs with CRP concentrations below this cut-off were excluded from the study when results of the CRP analysis were available. Based on clinical, hematological, and biochemical findings, an SPI2 (a logistic regression formula based on the parameters PCV, creatinine, albumin, mean arterial pressure, respiratory rate, age, and admitting service [medicine or surgery]) and an APPLE (a scoring system based on the parameters WBC, creatinine, total bilirubin, albumin, lactate, SpO2, respiratory rate, age, mentation, and presence of fluid in one or more body cavities) score were calculated for each dog with systemic inflammation. Both were calculated within 24 hours of ICU admission according to previously described methods. Clinical outcome was defined as survival or mortality 28 days postadmission and was determined through follow-up visits or telephone contact with the owner.

Healthy animals for a control group were recruited from hospital staff and veterinary students and determined healthy through physical examination, hematological and biochemical profiles, and echocardiography.

Blood Sampling and Analyses

For each dog, a hematological and biochemical analysis was performed at the time of ICU admission with automated analyzers, and cross checked by a board-certified clinical pathologist. Serum for analysis of cTnI, cTnT, and cytokines was obtained at the time of ICU admission and for CRP analysis at admission and 12–24 hours later. Serum was collected into gel separator tubes, allowed to clot for 30 minutes at room temperature, centrifuged for 10 minutes at 1,300 × g, separated, and stored in cryovials at −70°C within 2 hours of blood collection. Samples were stored for a maximum of 8 months until batch analysis. cTnI and cTnT were analyzed by commercially available high-sensitivity immunoassays, and the cTnI assay has recently been validated for use in companion animals, and the cTnT assay has been used previously for assessment of myocardial injury in dogs. CRP was analyzed by a commercially available turbidimetric immunoassay validated for canine use and calibrated with purified canine CRP. Serum cytokine activity was assessed by a canine-specific tumor necrosis factor-α (TNF-α) assay (detection limit: 2.4 pg/mL) and a canine-specific multiplex assay for interleukin-10 (IL-10) (detection limit: 1.6 pg/mL), IL-15 (detection limit: 14.8 pg/mL), IL-18 (detection limit: 4.6 pg/mL), and monocyte chemotactic protein-1 (MCP-1) (detection limit: 1.6 pg/mL) with an automated analyzer. The assays included internal quality control material.

Statistical Analyses

Data were assessed for normality by D’Agostino-Pearson omnibus test. Logarithmic transformation was applied where this assured a Gaussian distribution of otherwise nonparametric data. A two-tailed t-test was used to compare Gaussian data, and the Mann-Whitney U-test was used to compare non-Gaussian data. In a few cases, because of the fact that all control dogs had cTnT and IL-10 values below the detection limits of the assays, these animals were set to have concentrations corresponding to the detection limits, and the Wilcoxon Signed Rank test was used to test the data against a hypothetical value (the cut-off value of the assay in question). Correlations between cardiac markers, severity scores, and cytokines were assessed graphically as well as by Pearson’s or Spearman’s correlation coefficient where appropriate. The prognostic capability for 28-day mortality of the SPI2 and APPLE score models as well as of markers of cardiac injury were assessed by receiver operating characteristic (ROC) curve analysis. A significant prognosticator was defined as having an area under the curve (AUC) significantly greater than 0.5.
greater than 0.5. Where the AUC for a prognostic composite score and for a cardiac marker was significantly greater than 0.5, the cardiac marker was added to the scoring model by multiple logistic regression to determine whether it provided additional prognostic information to the model. The optimal combination of composite score and cardiac marker was obtained in a forward inclusion fashion. To investigate the suggested mediation of myocardial injury by inflammatory cytokines and its relation to prognosis, ROC curves were also created for each cytokine investigated, and those that had AUCs significantly greater than 0.5 were then added into the model individually in a forward inclusion fashion. Troponin and cytokine concentrations were logarithmically transformed to achieve Gaussian distribution for multiple logistic regression. Statistical significance was defined as P < .05. All statistical analyses were conducted by commercial statistical software (Normality, t-test, Mann–Whitney U-test, Wilcoxon’s test, correlations, ROC curve analysis, and multiple logistic regression).

Results

Study Population Characteristics

One hundred and six dogs were admitted to the ICU during the study period. Of these, 39 were excluded because of cardiac disease. Twelve dogs were excluded because data collection posed a risk to the animal, and four were excluded because the owner or the attending clinician declined inclusion of the dogs. Two dogs died in the ICU before inclusion in the study. Of the remaining 49 dogs, six did not meet the criteria of systemic inflammation at the time of admission and were excluded. In addition, 1 dog was excluded because it was euthanized because of a grave prognosis for mobility rather than a grave prognosis for survival. Thus, the study population consisted of 42 dogs. The 42 dogs were 1 female intact, 20 female spayed, and 21 male castrated dogs with an age span of 1–14 years (mean 7.0 years). Eight dogs were mixed breeds; all other dogs were purebreds of 23 different breeds, the most frequent being Labrador Retriever (n = 6), Boxer (n = 3), and French Bulldog (n = 3). Dogs presented with a primary diagnosis of trauma (n = 10), 5 dogs with polytrauma and 5 dogs with localized trauma), neoplasia (n = 8), gastrointestinal disease (n = 8), respiratory disease (n = 5), neurological disease (n = 4), hematological disease (n = 2), and various (n = 5: hemoabdomen caused by rupture of splenic hematoma [n = 2] and 1 of each of biliary mucocele, peritonitis, and GDV) diseases.

Eight dogs were used as healthy controls. The 8 dogs were 4 female spayed, 2 male intact, and 2 male castrated dogs with an age span of 1–9 years (mean 3.9 years). Two dogs were mixed breeds; all other dogs were purebreds of 6 different breeds.

Clinical Outcome

The 28-day case fatality rate was 26% (11/42 dogs). Ten dogs were euthanized during hospitalization because of the severity of clinical signs and perceived poor prognosis, and 1 dog died at home after discharge. One dog was lost to follow-up and was last seen 21 days after admission. The owner could not be reached after this date. As the dog was doing well on day 21, it was considered a survivor.

Severity Scores, Cardiac Troponins, and Cytokines

The median [range] APPLE score of the 42 dogs with systemic inflammation was 35 [16–54]. Nonsurvivors (41 [16–54]) had significantly higher APPLE scores than survivors (31 [17–48]) (Mann–Whitney, P = .0078). The median [range] SPI2 score was 0.71 [0.25–0.91]. There was no significant difference between SPI2 scores for survivors (0.72 [0.33–0.9]) and nonsurvivors (0.58 [0.25–0.91]) (Mann–Whitney, P = .11).

Admission cTnI concentrations were (median [range]) 0.416 [0.004–141.5] ng/mL. Forty of the 42 dogs (95.2%), including all non-survivors, had cTnI concentrations above the concentration range of the control dogs (0.01 [0.004–0.04] ng/mL) at the time of ICU admission. Non-survivors (2.64 [0.24–85.17] ng/mL) had significantly higher cTnI concentrations than survivors (0.20 [0.004–141.5] ng/mL) (based on ROC analysis) and control dogs (0.01 [0.004–0.04] ng/mL) (t-test, P < .001), and survivors had significantly higher cTnI concentrations than control dogs (t-test, P < .001) (Fig 1A). Admission cTnT concentrations were 13.5 [13–3,744] ng/L. Twenty-one dogs (50%), including 10 of 11 (91%) non-survivors, had cTnT concentrations above the detection limit of the assay (13 ng/L). All healthy dogs had cTnT concentrations below the detection limit. Nonsurvivors (46 [13–686] ng/L) had significantly higher cTnT concentrations than survivors (<13 [13–3,744] ng/L) (based on ROC analysis) and control dogs (all <13 ng/L) (Wilcoxon Signed Rank test, P = .002), and survivors had significantly higher cTnT concentrations than control dogs (Wilcoxon Signed Rank test, P = .001) (Fig 1B). Admission cTnI and cTnT concentrations were highly correlated (r = 0.91, Spearman, P < .001). No correlation was found between the cardiac troponins and the APPLE score (r = 0.20 [Spearman, P = .21] and r = 0.28 [Spearman, P = .07]) for correlation with cTnI and cTnT, respectively) or the SPI2 (r = −0.11 [Spearman, P = .51] and r = −0.15 [Spearman, P = .35] for correlation with cTnI and cTnT, respectively).

The APPLE score and both cardiac troponins were found to be significant prognosticators (Table 1). However, no significant prognostic capacity was identified for SPI2 in the examined cohort (Table 1). It was, therefore, not possible to investigate the significance of adding a marker of myocardial injury to this model.

The possible contribution of cardiac markers to the APPLE score was examined by multiple logistic regression. cTnI contributed significantly (P = .025) in a model combining the APPLE score and cTnI (coefficient estimate [95% CI]: 1.01 [0.04; 1.99]) corresponding to an odds ratio of 28-day mortality of 2.7 for each 10-fold increase in cTnI. There was no significant contribution of cTnT to the APPLE score (P = .16). Graphing the cTnI concentration against the APPLE score revealed that both prognosticators
had an excellent negative predictive value attributable to high prognostic sensitivity, but a less optimal positive predictive value attributable to compromised prognostic specificity (many false positives) when applied alone. The combination of cTnI and APPLE clearly reduced the number of false positives, and cTnI thus seemed to improve the prognostic specificity (and thereby the positive predictive value) of the model (Fig 2). As all animals that died had cTnI values above the optimal predictive cut-off (0.24 ng/mL) identified by the ROC analysis, the number of true positives (nonsurvivors predicted to die)—and thereby the prognostic sensitivity of the APPLE score—was not compromised by the inclusion of cTnI. For animals with cTnI concentrations above 0.24 ng/mL, 

<table>
<thead>
<tr>
<th>Variable</th>
<th>AUC-ROC</th>
<th>95% CI of AUC-ROC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity score</td>
<td>APPLE*</td>
<td>0.776 [0.621; 0.889]</td>
</tr>
<tr>
<td></td>
<td>SPI2</td>
<td>0.610 [0.447; 0.756]</td>
</tr>
<tr>
<td>Cardiac marker</td>
<td>cTnI*</td>
<td>0.801 [0.649; 0.907]</td>
</tr>
<tr>
<td></td>
<td>cTnT*</td>
<td>0.790 [0.637; 0.900]</td>
</tr>
</tbody>
</table>

AUC-ROC, area under the receiver operating characteristic curve; CI, confidence interval; APPLE, acute patient physiologic and laboratory evaluation; SPI2, survival prediction index; cTnI, cardiac troponin I; cTnT, cardiac troponin T.

*Indicates significant prognostic capacity.
the mortality rate was 45.8% whereas it was 0% for animals with concentrations below the cut-off.

One measurement of TNF-α was missing because of insufficient sample material. For TNF-α and MCP-1 there was a significant difference between dogs with systemic inflammation (TNF-α: 10.10 [6.36–23.35] pg/mL; MCP-1: 656.4 [104.6–1,609] pg/mL) and control dogs (TNF-α: 8.17 [6.26–9.42] pg/mL; MCP-1: 110.2 [94.69–198.9] pg/mL), however, no difference was found between nonsurvivors (TNF-α: 10.52 [7.57–18.41] pg/mL; MCP-1: 743.7 [193.6–1,506] pg/mL) and survivors (TNF-α: 10.1 [6.36–23.35] pg/mL; MCP-1: 591.8 [104.6–1,609] pg/mL) (Fig 3D,E). For IL-15 and IL-18 there was no significant difference between dogs with systemic inflammation (IL-15: 28.73 [<14.8–1,738] pg/mL; IL-18: 69.63 [<4.6–1,689] pg/mL) and control dogs (IL-15: 74.12 [24–307.5] pg/mL; IL-18: 89.22 [4.6–658] pg/mL); however, a significant difference was found between nonsurvivors (IL-15: 16 [<14.8–457.2] pg/mL; IL-18: 26.71 [<4.6–293.5] pg/mL) and survivors (IL-15: 60.23 [<14.8–1,738] pg/mL; IL-18: 79.39 [<4.6–1,689] pg/mL) (Fig 3B,C). For IL-10 there was a significant difference between dogs with systemic inflammation (8.5 [<1.6–145.6] pg/mL) and control dogs (all <1.6 pg/mL) as well as between nonsurvivors (14.33 [<1.6–98.64] pg/mL) and survivors (7.05 [<1.6–145.6] pg/mL) (Fig 3A). A significant correlation was found between cTnI and the cytokines IL-15 (r = –0.48, Spearman, P = .012) and IL-10 (r = 0.46, Pearson, P = .0023), but no correlation was found with TNF-α (r = 0.06, Spearman, P = .71), IL-18 (r = –0.16, Pearson, P = .32), or MCP-1 (r = –0.06, Spearman, P = .71).

IL-10, IL-15, and IL-18 were found to be significant prognosticators whereas TNF-α and MCP-1 were not (Table 2). Only IL-15 contributed significantly to the combined prognostic model of cTnI and APPLE (P = .024), and cTnI lost its significance when IL-15 was added to the model (P = .16).

**Discussion**

This study documents a clinically important degree of myocardial cell injury occurring in dogs with systemic inflammation and without primary cardiac disease. Presence of myocardial injury was predictive of short-term survival, and cTnI as a marker of myocardial injury contributed independently to the established prognostic composite score, APPLE, by providing additional prognostic specificity without compromising prognostic sensitivity. The inflammatory cytokine IL-15 was correlated with cTnI and identified as a significant coexplanatory factor for the prognostic value of cTnI.

The importance of the heart in critical disease is hardly surprising. However, although objective markers of injury and function for several other organs have been routinely measured for decades, no cardiac marker has been a part of a routine work-up in critically ill dogs. It seems from the findings of this study that the cardiac troponins, especially cTnI, may be useful for this purpose. The superiority of cTnI over cTnT in this study may be because of the fact that, although they supply similar information, cTnI levels generally increase with less severe disease than those of cTnT, suggesting that cTnI is a more sensitive marker of myocardial injury. The reason for this difference in release is unknown, but may be because of a difference in protein size and molecular weight or the fact that cTnI may be degraded into fragments after the brief periods of myocardial ischemia. In cases of irreversible myocardial injury, it has also been speculated that cTnT may have a structurally closer binding to the tropomyosin chain than cTnI.

Human studies have revealed that the presence of myocardial injury is associated with increased morbidity and mortality, though clinically it is often unrecognized. In fact, patients with increased troponin concentrations can have similar clinical characteristics as those without evidence of cardiac injury. Considering that cardiac troponins are primarily used in the diagnosis of AMI, it is notable that mortality for critically ill patients with myocardial injury can be as high as or higher than that of patients in whom cardiac troponins were increased because of a primary cardiac disease or AMI. This is even more interesting when it is considered that patients with clinically unrecognized cardiac injury generally have significantly lower concentrations of cTnI than those with diagnosed AMI. Consequently, it seems that the presence of myocardial injury in itself rather than just the degree of injury accounts for a worse prognosis.

In several human studies, cTnI in critically ill patients remained an independent prognosticator even after stratifying for illness severity by use of a severity score. As is the case for veterinary severity scores, human severity scores such as APACHE and SAPS evaluate hemodynamic changes rather than the status of the heart itself, and it may be argued that myocardial injury, thus not accounted for by these scores, supplies additional prognostic information. The contribution to the prognostic capacity of the APPLE score by cTnI in this study was highly significant. The effect of cTnI was to improve the prognostic specificity of the model. As the model’s prognostic sensitivity was not compromised, it may be of value to include a marker of myocardial injury in prognostic severity scores in the future. It is also noteworthy that the dogs included in this study had received varying degrees of volume resuscitation before ICU admission. The prognostic capacity of the cardiac markers was verified in spite of this possible interference, thereby further strengthening their use in a clinical setting.

Although the APPLE score in itself was a significant prognosticator in this study, surprisingly, SPI2 was not. The cohort of dogs in this study had a survival rate of 73.8% which is within the range of survival rates for which the SPI2 was validated. However, this cohort was selected based on the presence of systemic inflammation, and all dogs without evidence of systemic inflammation were excluded. As dogs with systemic inflammation were included in the construction...
Fig 3. Serum interleukin (IL)-10 (A), IL-15 (B), IL-18 (C), monocyte chemo-attractant protein-1 (MCP-1) (D), and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) (E) concentrations of critically ill dogs with systemic inflammation (\(n = 42\)) and healthy control dogs (\(n = 8\)) as well as of survivors and non-survivors. Geometric mean of concentrations (B, C) for Gaussian and medians (A, D, E) for non-Gaussian data are shown as horizontal lines. Significant differences between groups are symbolized with * (receiver operating characteristic curve analysis with a 95% confidence interval not including .5), x (Wilcoxon Signed Rank test), and + (Mann–Whitney U-test).
Table 2. Prognostic capacity of various cytokines in 42 critically ill dogs with systemic inflammation evaluated by analysis of receiver operating characteristic curves (ROCs).

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>AUC-ROC</th>
<th>95% CI of AUC-ROC</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-10*</td>
<td>0.679</td>
<td>[0.517; 0.814]</td>
</tr>
<tr>
<td>IL-15*</td>
<td>0.723</td>
<td>[0.563; 0.849]</td>
</tr>
<tr>
<td>IL-18*</td>
<td>0.694</td>
<td>[0.532; 0.826]</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.575</td>
<td>[0.413; 0.726]</td>
</tr>
<tr>
<td>TNF-α</td>
<td>0.503</td>
<td>[0.343; 0.663]</td>
</tr>
</tbody>
</table>

AUC-ROC, area under the receiver operating characteristic curve; CI, confidence interval; IL, interleukin; MCP-1, monocyte chemo-attractant protein-1; TNF-α, tumor necrosis factor-α.

*Indicates significant prognostic capacity.

of both the SPI2 and the APPLE score,34 we used the scores in a patient group for which the scores have already been validated. Nevertheless, both scores were constructed with a less selected ICU population, giving a possible explanation for the reduced performance of the scores in these cohort when compared to construction and validation cohorts.

Prognostic composite scores assist clinicians in supplementing their clinical judgment with objective measures of patient illness and have been shown to improve clinicians’ accuracy of survival prediction.29,30 Optimizing the predictive sensitivity and specificity of such scores is therefore desirable, and this study identifies a possible need for inclusion of the status of the myocardium in prognostic scoring. cTnI in itself as well as the APPLE score had an excellent negative predictive value, but a less optimal positive predictive value. This may be because of the fact that myocardial injury might be reversible in inflammatory diseases. Reversible myocardial depression associated with sepsis has been recognized in 40–50% of people with this disease,31,32 and in fact many of these people survive.33 Reversible myocardial injury has been explained by several theories. One theory advocates cytokine-mediated myocardial cell injury leading to myocardial “cell membrane gaps” with leakage of troponins into the extracellular fluid.5,14,16 Another theory suggests reversible ischemia induced by an activated clotting system in sepsis or SIRS causing microcirculatory thrombosis, a theory that was rejected in a recent study.34 Finally, it has been postulated that reversible myocardial injury may be because of incomplete apoptosis.35,36 Most likely, it is a combination of several factors. The theory of cytokine-mediated myocardial injury has gained most of the attention in research. Experimental studies indicate that cytokines such as TNF-α may lead to an increased permeability of the cardiomyocyte membrane for macromolecules such as the troponins.37,38 Cytokines are also thought to mediate decreased cardiac contractility39 which often accompanies sepsis. In 1 study of experimental endotoxemia, however, increased TNF-α, IL-6, and IL-8 were not followed by an increase in cTnI, and it was speculated that a longer proinflammatory mediator exposure or a concurrent exposure to changes in additional cytokine concentrations were necessary for cardiac injury to take place.14 In this study, TNF-α was not correlated with cTnI or cTnT and was not a significant prognosticator in itself. The cytokines IL-10, IL-15, and IL-18, however, were significant prognosticators. IL-15 remained significant in a model combining the APPLE score and cTnI, and, interestingly, cTnI lost its significance when IL-15 was added to the model. This coexplanatory correlation as a predictor of outcome may be coupled to etiology and supports the suggested contribution of cytokines to myocardial injury. Experimental evidence exists of IL-15 treatment having a beneficial effect in mice with virus-induced myocarditis40 which further supports our findings of significantly higher cTnI concentrations and lower IL-15 concentrations in nonsurvivors compared to survivors. Further studies will have to be conducted to elucidate the possible etiological correlation.

An important limitation of this study was the fact that the model created combining the APPLE score with cTnI was not validated in a separate cohort of dogs. A multicenter study including a larger cohort of dogs with systemic inflammation would be valuable for further evaluation of the benefit of including markers of myocardial injury in composite severity scores. Secondly, a source of error inherent to veterinary survival studies was created when decisions were made to include dogs that were euthanized rather than only dogs that died naturally. Some nonsurvivors might, in fact, have survived, had treatment been continued. APPLE and SPI2, the 2 diagnosis-independent severity scores validated for use in dogs, both include euthanized dogs, but SPI2 attempts to minimize this error by only including dogs that are euthanized because of a grave prognosis for survival.34,35 Accordingly, these criteria were applied to this study as well. Thirdly, it cannot be excluded that a degree of mechanical cardiac injury may have occurred in the 5 dogs with polytrauma, causing potential bias. The dogs were equally distributed among the population with regard to cTnI concentrations and APPLE scores, exclusion from statistical analysis did not change any of the specific findings (data not shown), and as inflammatory cardiac injury was likely to be involved, these dogs were not excluded from the study. A 4th limitation was the fact that the analytical sensitivity of the assays for cTnT and IL-10 was insufficient, where the value of the detection limit was assigned to several samples with a risk of violation of statistical assumptions. However, as graphical examination of the data for both variables revealed a considerable difference between dogs with systemic inflammation and control dogs, the test results were considered valid. Finally, to ensure exclusion of primary cardiac disease, it is possible that a few dogs with decreased contractility were excluded as it may resemble mild DCM. This may have reduced the size of our study population, but was not thought to cause a bias as it only strengthened our certainty of a cardiac disease-free population. Nevertheless, a few study-eligible dogs with critical
illness-induced myocardial dysfunction may have been wrongly excluded, but valvular disease was, by far, the most common cause of exclusion. In conclusion, markers of myocardial injury were found to be predictive of 28-day case fatality in critically ill dogs with systemic inflammation and without a primary cardiac diagnosis. cTnI significantly contributed to the prognostic composite score, APPLE, by improving prognostic specificity without compromising prognostic sensitivity and thus may be valuable in construction of future severity scores. Finally, IL-15 might play a role in the sequence of events leading to myocardial injury in these dogs.

Footnotes

2 Scil vet ABC hematology analyzer; Horiba ABX, Northampton, UK
3 Vitros 350 chemistry analyzer; Orthoclinial Diagnostics, Johnson and Johnson, Rochester, NY
4 ADVIA Centaur CP TnI-ultra; Siemens Healthcare Diagnostics Inc, Tarrytown, NY
5 Canary C-reactive Protein; LifeDiagnostics, West Chester, PA
6 Quantikine CATA00; R&D Systems Inc, Minneapolis, MN
7 CCYTO-90K; Millipore Corporation, Billerica, MA
8 Lumexin 200; Lumexin Corporation, Austin, TX
9 GraphPad Prism 5.01 for Windows; GraphPad Software, San Diego, CA
10 MedCalc 6.00.012; MedCalc Software, Mariakerke, Belgium
11 SAS 9.2; SAS Institute Inc, Cary, NC

Acknowledgments

The authors thank Prof. Jens Peter Goetze, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Denmark, for assistance with cardiac troponin T measurements and the staff at Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania for help with inclusion of dogs for the study. Part of the study was funded through research grants from Knud Højgaard’s Fund, Denmark, and the Oticon Fund, Denmark.

Conflict of Interest Declaration: Authors disclose no conflict of interest.

References


